Background: The object of this paper was to provide an overview of rare diseases (RDs) with
periodontal manifestations and allocate them to relevant categories. Methods: In ROMSE, a …

While several genetic and morphological markers are established and serve to guide
therapy of acute myeloid leukaemia (AML), there is still profound need to identify additional …

Immunotherapy of acute myeloid leukemia (AML) has been challenging because the lack of
tumor-specific antigens results in" on-target, off-tumor" toxicity. To unlock the full potential of …

Despite the increasing knowledge of the genomic landscape of acute myeloid leukemia
(AML), prediction merely based on genetics fails to anticipate outcome, presumably due to …

Simple Summary FLT3 gene mutations are among the most common genetic aberrations
detected in AML and occur with a frequency of approximately 30%, mainly as internal …

The oncometabolite 2-hydroxyglutarate (2-HG) plays a key role in differentiation blockade
and metabolic reprogramming of cancer cells. Approximatively 20–30% of acute myeloid …

The aim of the present study was to examine the expression and clinical significance of long
non‑coding RNA (lncRNA)‑CCDC26 in patients with acute myeloid leukemia (AML), and to …

Vesicular stomatitis virus (VSV) represents an attractive oncolytic virotherapy platform
because of its potent tumor cell-killing and immune-stimulating properties; yet the clinical …

Mutations in FMS-like tyrosine kinase 3 (FLT3) gene occur frequently in acute myeloid
leukemia (AML) and are rare in acute lymphoblastic leukemia (ALL). We aimed to analyze …

Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …